NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Source: onclive.com
Nexcella Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nexcella Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nexcella Inc Today - Breaking & Trending Today
European Commission Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis
NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.
Source: onclive.com
Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational...
Source: globenewswire.com
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain ...
Source: marketscreener.com
Nexcella Announces FDA Approval of IND Application for
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with...
Source: globenewswire.com